Haematological malignancies

825O - Ivosidenib in Chinese patients (pts) with relapsed/refractory acute myeloid leukemia (R/R AML) with an IDH1 mutation: Results from a bridging registrational study

Wang, et al.

Conclusions

Ivosidenib was well tolerated and induced durable remissions with clinical benefits in Chinese pts with mIDH1 R/R AML, potentially fulfilling an unmet medical need for this rare pt population in China.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/825O.html.pdf

826O - Copanlisib plus rituximab vs placebo plus rituximab in patients (pts) with relapsed marginal zone lymphoma (MZL) treated in the phase III CHRONOS-3 trial

Muhit Özcan, et al.

Conclusions

C+R showed superior efficacy vs P+R in pts with relapsed MZL, including nodal MZL. The safety profile of C+R was consistent with C and R as monotherapy. Copanlisib is the first PI3K inhibitor to be safely combined with R in a phase III setting in pts with relapsed MZL and represents a new therapeutic strategy.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/826O.html.pdf

833O - A phase Ib study result of HMPL-689, a PI3Kδ inhibitor, in Chinese patients with relapsed/refractory lymphoma

Junning Cao, et al.

Conclusions

HMPL-689 showed tolerable safety profile and promising single-agent clinical activity in pts with R/R B-cell lymphoma, with high ORR and CR rates noted particularly for FL patients.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/833O.html.pdf